Now showing items 1-1 of 1
Cabo, Mariona (Date of defense: 2019-11-08)
HER2 overexpression accounts for approximately 15-20% of breast tumors, and mainstay therapy for these patients includes HER2-specific antibodies in combination with chemotherapy. Although the efficacy of anti-HER2 antibodies ...